DrugPatentWatch Database Preview

Details for Patent: 8,410,167

« Back to Dashboard

Which drugs does patent 8,410,167 protect, and when does it expire?

Patent 8,410,167 protects MULTAQ and is included in one NDA.

This patent has fifty-nine patent family members in twenty-nine countries.

Summary for Patent: 8,410,167

Title:	Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
Abstract:	Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Inventor(s):	Radzik; Davide (Paris, FR), Van Eickels; Martin (Berlin, DE), Hamdani; Nacera (Paris, FR), Gaudin; Christophe (Paris, FR)
Assignee:	SANOFI (Paris, FR)
Application Number:	12/425,125
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,410,167
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,410,167

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sanofi Aventis Us	MULTAQ	dronedarone hydrochloride	TABLET;ORAL	022425-001	Jul 1, 2009		RX	Yes	Yes

Foreign Priority and PCT Information for Patent: 8,410,167

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	08 02127	Apr 17, 2008
France	08 03208	Jun 10, 2008
	09290095	Feb 11, 2009
	09290098	Feb 11, 2009

International Family Members for US Patent 8,410,167

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072950
Argentina	072951
Australia	2009252897
Australia	2009252898